BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 15109626)

  • 1. Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand.
    Nishino N; Yoshikawa D; Watanabe LA; Kato T; Jose B; Komatsu Y; Sumida Y; Yoshida M
    Bioorg Med Chem Lett; 2004 May; 14(10):2427-31. PubMed ID: 15109626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases.
    Bhuiyan MP; Kato T; Okauchi T; Nishino N; Maeda S; Nishino TG; Yoshida M
    Bioorg Med Chem; 2006 May; 14(10):3438-46. PubMed ID: 16439135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of aliphatic cap group in inhibition of histone deacetylases by cyclic tetrapeptides.
    Nishino N; Shivashimpi GM; Soni PB; Bhuiyan MP; Kato T; Maeda S; Nishino TG; Yoshida M
    Bioorg Med Chem; 2008 Jan; 16(1):437-45. PubMed ID: 17900911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones.
    Jose B; Oniki Y; Kato T; Nishino N; Sumida Y; Yoshida M
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5343-6. PubMed ID: 15454224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
    Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
    Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework.
    Shivashimpi GM; Amagai S; Kato T; Nishino N; Maeda S; Nishino TG; Yoshida M
    Bioorg Med Chem; 2007 Dec; 15(24):7830-9. PubMed ID: 17881232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic tetrapeptides bearing a sulfhydryl group potently inhibit histone deacetylases.
    Nishino N; Jose B; Okamura S; Ebisusaki S; Kato T; Sumida Y; Yoshida M
    Org Lett; 2003 Dec; 5(26):5079-82. PubMed ID: 14682769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
    Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents.
    Guandalini L; Cellai C; Laurenzana A; Scapecchi S; Paoletti F; Romanelli MN
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5071-4. PubMed ID: 18723349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.
    Chen PC; Patil V; Guerrant W; Green P; Oyelere AK
    Bioorg Med Chem; 2008 May; 16(9):4839-53. PubMed ID: 18397827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward an HDAC6 inhibitor: synthesis and conformational analysis of cyclic hexapeptide hydroxamic acid designed from alpha-tubulin sequence.
    Jose B; Okamura S; Kato T; Nishino N; Sumida Y; Yoshida M
    Bioorg Med Chem; 2004 Mar; 12(6):1351-6. PubMed ID: 15018907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.
    Hanessian S; Auzzas L; Giannini G; Marzi M; Cabri W; Barbarino M; Vesci L; Pisano C
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6261-5. PubMed ID: 17892933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
    Bouchain G; Leit S; Frechette S; Khalil EA; Lavoie R; Moradei O; Woo SH; Fournel M; Yan PT; Kalita A; Trachy-Bourget MC; Beaulieu C; Li Z; Robert MF; MacLeod AR; Besterman JM; Delorme D
    J Med Chem; 2003 Feb; 46(5):820-30. PubMed ID: 12593661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chlamydocin-hydroxamic acid analogues as histone deacetylase inhibitors.
    Nishino N; Jose B; Shinta R; Kato T; Komatsu Y; Yoshida M
    Bioorg Med Chem; 2004 Nov; 12(22):5777-84. PubMed ID: 15498654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular modeling studies toward the structural optimization of new cyclopeptide-based HDAC inhibitors modeled on the natural product FR235222.
    Di Micco S; Terracciano S; Bruno I; Rodriquez M; Riccio R; Taddei M; Bifulco G
    Bioorg Med Chem; 2008 Sep; 16(18):8635-42. PubMed ID: 18715788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors.
    Angibaud P; Arts J; Van Emelen K; Poncelet V; Pilatte I; Roux B; Van Brandt S; Verdonck M; De Winter H; Ten Holte P; Marien A; Floren W; Janssens B; Van Dun J; Aerts A; Van Gompel J; Gaurrand S; Queguiner L; Argoullon JM; Van Hijfte L; Freyne E; Janicot M
    Eur J Med Chem; 2005 Jun; 40(6):597-606. PubMed ID: 15922843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
    Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of a potent histone deacetylase inhibitor.
    Liu T; Kapustin G; Etzkorn FA
    J Med Chem; 2007 May; 50(9):2003-6. PubMed ID: 17419603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, evaluation and molecular modeling of cyclic tetrapeptide histone deacetylase inhibitors as anticancer agents.
    Huang D; Li X; Sun L; Xiu Z; Nishino N
    J Pept Sci; 2012 Apr; 18(4):242-51. PubMed ID: 22253009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.